Boston Scientific (NYSE:BSX) has received a consensus recommendation of “Buy” from the twenty-five analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $32.38.
Several equities analysts have recently issued reports on BSX shares. Canaccord Genuity reissued a “buy” rating and issued a $36.00 price target on shares of Boston Scientific in a report on Wednesday, April 25th. Bank of America boosted their price target on shares of Boston Scientific from $30.00 to $34.00 and gave the company a “buy” rating in a report on Thursday, April 5th. Needham & Company LLC reissued a “buy” rating and issued a $35.00 price target on shares of Boston Scientific in a report on Tuesday, March 27th. Citigroup boosted their price target on shares of Boston Scientific from $32.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday, May 1st. Finally, ValuEngine raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd.
Shares of Boston Scientific opened at $30.31 on Thursday, Marketbeat.com reports. Boston Scientific has a 12-month low of $24.54 and a 12-month high of $30.84. The firm has a market capitalization of $41.82 billion, a PE ratio of 24.06, a PEG ratio of 2.16 and a beta of 0.81. The company has a debt-to-equity ratio of 0.68, a current ratio of 0.82 and a quick ratio of 0.59.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 25th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. Boston Scientific had a net margin of 1.21% and a return on equity of 25.10%. The company had revenue of $2.38 billion during the quarter, compared to analyst estimates of $2.34 billion. During the same quarter in the previous year, the business earned $0.29 EPS. The firm’s revenue was up 10.1% on a year-over-year basis. equities analysts expect that Boston Scientific will post 1.39 EPS for the current fiscal year.
In other news, SVP Eric Francis Yves Thepaut sold 20,015 shares of the stock in a transaction dated Thursday, May 17th. The shares were sold at an average price of $30.15, for a total transaction of $603,452.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP John Bradley Sorenson sold 1,950 shares of the stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $27.43, for a total transaction of $53,488.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 180,241 shares of company stock valued at $5,169,313. Company insiders own 0.73% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Truewealth LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $116,000. Icon Wealth Partners LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $117,000. Cerebellum GP LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $126,000. Delpha Capital Management LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $135,000. Finally, Ostrum Asset Management bought a new stake in shares of Boston Scientific in the 1st quarter valued at about $174,000. Institutional investors own 89.38% of the company’s stock.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.